Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Illumina Inc (NASDAQ:ILMN)

162.25
Delayed Data
As of Jul 27
 +12.15 / +8.09%
Today’s Change
127.10
Today|||52-Week Range
220.86
-15.47%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$22.1B

Company Description

Illumina, Inc. develops, manufactures and markets integrated systems for the analysis of genetic variation and function. The company provides sequencing and array-based solutions for genetic analysis in addition to selling products, it provide genotyping, NIPT and whole-genome sequencing services. Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals, and reference laboratories as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic, and consumer genomics companies. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Contact Information

Illumina, Inc.
5200 Illumina Way
San Diego California 92122
P:(858) 202-4500
Investor Relations:
(858) 255-5243

Employees

Shareholders

Individual stakeholders6.57%
Mutual fund holders58.59%
Other institutional39.06%

Top Executives

Francis A. deSouzaPresident, Chief Executive Officer & Director
Robert P. RagusaSenior Vice President-Global Quality & Operations
Marc A. StapleyEVP, Chief Financial & Administrative Officer
Mostafa RonaghiChief Technology Officer & Senior Vice President
Norman FjeldheimChief Information Officer